Meanings
- uncountablemedicineA medication belonging to the class of Janus kinase inhibitors, used for the treatment of several diseases including myelofibrosis and polycythemia vera.
For example, Gallipoli et al. reported that combination of nilotinib with ruxolitinib could induce apoptosis in chronic myeloid leukemia (CML) stem cells through inhibiting JAK-2/STAT-5 signaling pathway.
2015 July 14, Li Zhang, Handong Wang, Orazio Taglialatela-Scafati, “Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin”, in Marine Drugs, volume 13, →DOI1 more example
The first jakinib to enter clinical trials, initially for renal transplantation, was tofacitinib, which inhibits JAK1/JAK2/JAK3; however, ruxolitinib, a JAK1/JAK2 inhibitor, was the first agent to receive approval, as a treatment for myeloproliferative neoplasms that often exhibit gain-of-function JAK2 mutations.
2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2168
Cite this entry
ruxolitinib. (n.d.). In WatkinsX Dictionary. Retrieved November 5, 2026, from https://dictionary.watkinsx.com/word/ruxolitinib
“ruxolitinib.” WatkinsX Dictionary, https://dictionary.watkinsx.com/word/ruxolitinib. Accessed November 5, 2026.
WatkinsX Dictionary, s.v. “ruxolitinib,” accessed November 5, 2026, https://dictionary.watkinsx.com/word/ruxolitinib.
Source: ruxolitinib on Wiktionary, CC BY-SA 4.0.